Viva Biotech Holdings - Asset Resilience Ratio
Viva Biotech Holdings (VB0) has an Asset Resilience Ratio of 6.39% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check VB0 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2020)
This chart shows how Viva Biotech Holdings's Asset Resilience Ratio has changed over time. See how leveraged is Viva Biotech Holdings's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Viva Biotech Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see VB0 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €504.93 Million | 6.39% |
| Total Liquid Assets | €504.93 Million | 6.39% |
Asset Resilience Insights
- Limited Liquidity: Viva Biotech Holdings maintains only 6.39% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Viva Biotech Holdings Industry Peers by Asset Resilience Ratio
Compare Viva Biotech Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Viva Biotech Holdings (2017–2020)
The table below shows the annual Asset Resilience Ratio data for Viva Biotech Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.61% | €49.50 Million ≈ $57.87 Million |
€8.15 Billion ≈ $9.53 Billion |
-0.95pp |
| 2019-12-31 | 1.56% | €29.63 Million ≈ $34.64 Million |
€1.90 Billion ≈ $2.22 Billion |
-0.17pp |
| 2017-12-31 | 1.73% | €3.50 Million ≈ $4.09 Million |
€202.40 Million ≈ $236.63 Million |
-- |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more